AP2014007738A0 - Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists - Google Patents

Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists

Info

Publication number
AP2014007738A0
AP2014007738A0 AP2014007738A AP2014007738A AP2014007738A0 AP 2014007738 A0 AP2014007738 A0 AP 2014007738A0 AP 2014007738 A AP2014007738 A AP 2014007738A AP 2014007738 A AP2014007738 A AP 2014007738A AP 2014007738 A0 AP2014007738 A0 AP 2014007738A0
Authority
AP
ARIPO
Prior art keywords
gonadotropin
receptor antagonists
hormone receptor
releasing hormone
spiroindoline derivatives
Prior art date
Application number
AP2014007738A
Other languages
English (en)
Inventor
Eckhard Bender
Mark Jean Gnoth
Reinhard Nubbemeyer
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47559493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007738(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AP2014007738A0 publication Critical patent/AP2014007738A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AP2014007738A 2012-01-16 2013-01-15 Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists AP2014007738A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12151291 2012-01-16
PCT/EP2013/050676 WO2013107743A1 (fr) 2012-01-16 2013-01-15 Dérivés de la spiroindoline comme antagonistes du récepteur de l'hormone libérant la gonatrophine (gnrh)

Publications (1)

Publication Number Publication Date
AP2014007738A0 true AP2014007738A0 (en) 2014-07-31

Family

ID=47559493

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007738A AP2014007738A0 (en) 2012-01-16 2013-01-15 Spiroindoline derivatives as gonadotropin-releasing hormone receptor antagonists

Country Status (25)

Country Link
US (1) US20140357655A1 (fr)
EP (1) EP2804867A1 (fr)
JP (1) JP2015503607A (fr)
KR (1) KR20140112075A (fr)
CN (1) CN104169287A (fr)
AP (1) AP2014007738A0 (fr)
AU (1) AU2013211091A1 (fr)
BR (1) BR112014017483A8 (fr)
CA (1) CA2860986A1 (fr)
CL (1) CL2014001871A1 (fr)
CO (1) CO7010832A2 (fr)
CR (1) CR20140343A (fr)
CU (1) CU20140088A7 (fr)
DO (1) DOP2014000167A (fr)
EA (1) EA201491344A1 (fr)
GT (1) GT201400153A (fr)
HK (1) HK1199878A1 (fr)
IL (1) IL233485A0 (fr)
MA (1) MA35867B1 (fr)
MX (1) MX2014008630A (fr)
PE (1) PE20141699A1 (fr)
PH (1) PH12014501616A1 (fr)
SG (1) SG11201403749VA (fr)
TN (1) TN2014000306A1 (fr)
WO (1) WO2013107743A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095785A1 (es) * 2013-04-09 2015-11-11 Bayer Pharma AG Derivados de espiroindolina y composiciones farmacéutica de los mismos
WO2015007606A1 (fr) * 2013-07-15 2015-01-22 Bayer Pharma Aktiengesellschaft Dérivés de spiroindoline et leurs compositions pharmaceutiques
WO2015082374A1 (fr) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Dérivés spiro indoline-thiopyrane-imine-oxydes utilisés comme antagonistes du récepteur de l'hormone de libération des gonadotrophines et compositions pharmaceutiques associées
EP2881391A1 (fr) 2013-12-05 2015-06-10 Bayer Pharma Aktiengesellschaft Dérivés de carbocycle spiroindoline et leurs compositions pharmaceutiques
WO2015091315A1 (fr) * 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Dérivés de spiro[indoline-3,4'-pipéridine] utilisés comme antagonistes du récepteur gnrh
EP3339846B1 (fr) * 2016-12-22 2020-12-09 Malvern Panalytical B.V. Procédé de mesure des propriétés d'une empilement de couches minces
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN107840851A (zh) * 2017-12-21 2018-03-27 扬州大学 吲哚螺吡咯嗪化合物及其合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds

Also Published As

Publication number Publication date
CL2014001871A1 (es) 2014-11-03
TN2014000306A1 (en) 2015-12-21
HK1199878A1 (en) 2015-07-24
WO2013107743A1 (fr) 2013-07-25
BR112014017483A2 (pt) 2017-06-13
MA35867B1 (fr) 2014-12-01
GT201400153A (es) 2015-05-22
US20140357655A1 (en) 2014-12-04
JP2015503607A (ja) 2015-02-02
CA2860986A1 (fr) 2013-07-25
IL233485A0 (en) 2014-08-31
PH12014501616A1 (en) 2014-10-13
KR20140112075A (ko) 2014-09-22
CN104169287A (zh) 2014-11-26
CO7010832A2 (es) 2014-07-31
CU20140088A7 (es) 2014-12-26
DOP2014000167A (es) 2014-08-31
SG11201403749VA (en) 2014-07-30
AU2013211091A1 (en) 2014-08-07
EP2804867A1 (fr) 2014-11-26
BR112014017483A8 (pt) 2017-07-04
CR20140343A (es) 2014-09-08
PE20141699A1 (es) 2014-11-29
EA201491344A1 (ru) 2015-04-30
MX2014008630A (es) 2014-08-29

Similar Documents

Publication Publication Date Title
IL233592A0 (en) p2x4 receptor antagonist
ZA201500781B (en) 5-ht3 receptor antagonists
IL233485A0 (en) History of spiroindoline as gonadotropin-releasing hormone receptor antagonists
PL2736918T3 (pl) Antagoniści progesteronu
PT3524230T (pt) Formulações farmacêuticas que compreendem antagonistas de ccr3
IL244356A0 (en) Formulations for cgrp receptor antagonists
PT2935227T (pt) Amidas diazol como antagonistas do recetor ccr1
GB201223053D0 (en) Receptor
IL241815B (en) Dosage form of a progesterone receptor antagonist
PT2714647E (pt) Derivativos bifenil usados como antagonistas do recetor da glicagina
ZA201508209B (en) Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists
GB201213699D0 (en) Receptor antagonists II
GB201213698D0 (en) Receptor antagonists II